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INTEGRATIVE GENOMICS IMPLICATES DISRUPTION OF PRENATAL 
NEUROGENESIS IN CONGENITAL HYDROCEPHALUS 
Shreyas Panchagnula and Kristopher T. Kahle. Section of Pediatric Neurosurgery, 
Department of Neurosurgery, Yale University, School of Medicine, New Haven, CT. 
 
Congenital Hydrocephalus (CH) affects 1/1000 live births and costs the US healthcare 
system over $2 billion annually. Mainstay therapies, hinging on surgical cerebrospinal fluid 
diversion, exhibit high failure rates and substantial morbidity. Limited understanding of 
pathogenesis warrants identification of crucial genetic drivers underlying CH and their 
impact on brain development. This pioneering study integrates gene discovery from the 
largest whole-exome sequenced CH cohort with transcriptional networks (modules) and 
cell-type markers from the latest transcriptomic atlases of the mid-gestational human brain 
to uncover the genomic and molecular architecture of CH. Exome analysis of 381 
radiographically-confirmed, neurosurgically-treated sporadic CH probands (including 232 
case-parent trios) identified genes with rare de novo or transmitted mutations conferring 
disease risk. Transcriptome analyses identified mid-gestational brain modules and cell-
types enriched for cohort-determined CH risk genes, known genes previously implicated 
in isolated and syndromic forms of CH, and risk genes of Autism Spectrum Disorder (ASD) 
and Developmental Disorder (DD). Genetic drivers of CH converge in a 
neurodevelopmental network and in early neurogenic cell-types, implicating genetic 
disruption of early brain development as a primary patho-mechanism for a significant 
 iii 
subset of CH patients. Genetic and transcriptional overlap with ASD and DD may explain 
persistence of these conditions in CH patients despite surgical intervention, while greater 
potency of CH-enriched neural precursors may account for increased frequency of 
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IV. An Introduction to Congenital Hydrocephalus 
Hydrocephalus is the most common disease seen in pediatric neurosurgical 
practices1, with a prevalence of roughly 1.1 per 1000 births2 and a cost of $2 billion to the 
US healthcare system alone3. Hydrocephalus is classically defined as the active, 
progressive distension of the cerebral ventricular system (i.e. ventriculomegaly) resulting 
from the inadequate passage of cerebrospinal fluid (CSF) from its main site of production 
at the choroid plexus epithelium (CPe) to its site of reabsorption into the systemic 
circulation (e.g. the arachnoid granulations).4-8 The standard classification scheme of 
hydrocephalus rests on two fundamental features: etiology, and the anatomy of the CSF 
conduit.1,8-11 Hydrocephalus can be acquired (secondary) or congenital (primary) based on 
the presence or absence of a known etiological antecedent, respectively. The most common 
forms of secondary hydrocephalus include post-hemorrhagic hydrocephalus (PHH) and 
postinfectious hydrocephalus.1,8,11-13 Hydrocephalus can also be non-communicating or 
communicating based on the presence or absence of obstruction to CSF flow, respectively.1 
Here I review congenital hydrocephalus, including the relevant anatomy and physiology of 
the developing brain, pathophysiology, clinical features, etiologies, and genetic 
mechanisms. 
Anatomy and Physiology of the Developing Brain Parenchyma and Ventricular 
System 
The pathogenesis of hydrocephalus coincides with key processes pertaining to the 
development of the brain. Here I will describe some of these neurodevelopmental processes 
of the brain parenchyma and the ventricular system. 
 2 
Neural development begins when the notochord induces the ectoderm to 
differentiate into the neural plate. Through the process of neurulation, the neural plate folds 
and fuses to form the neural tube. The development of the neural tube creates a lumen that 
becomes the ventricular system, which encloses CSF and is surrounded by brain 
parenchymal tissue.14 At the interface of the ventricular system and brain parenchyma lies 
a special layer termed the neuroepithelium.15 This pseudostratified epithelium contains 
self-renewing neuro-epithelial cells studded with punctate and tight adhesion junctions and 
demonstrates selective permeability.16 Owing to myosin regulation, the stretchy 
neuroepithelium demonstrates elasticity and relaxation to accommodate shaping and 
expansion of the ventricular cavities.17 
Two germinal zones arise from the neuroepithelium lining the ventricular wall: the 
ventricular zone (VZ), and the subventricular zone (SVZ).14,18-21 The VZ contains neuro-
epithelial cells that differentiate into self-renewing multipotent neural stem cells14, while 
the SVZ contains neural progenitors that originate from neural stem cells in the VZ19. In 
human brain development, the period of 12 to 18 gestational weeks marks important 
processes of neurogenesis, including neural proliferation and migration of nascent neurons 
from the germinal zones to the outer cortex of the developing brain.22 
In the early ventricular system, CSF is first produced primarily by the 
neuroepithelium15, evident from neuroepithelial CSF production studies in several model 
organisms23-25, and consistent with the presence of CSF in human brain ventricles ~3-4 
weeks before the maturation of a set of specialized vascularized epithelial sheets called the 
choroid plexus26. From the sixth week of gestation, the choroid plexus becomes the main 
site of CSF production.7 The bulk flow model explains the conduit of CSF flow from its 
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origin in the choroid plexus to its absorption in the arachnoid granulations.27 CSF flow 
starts in the lateral ventricles and continues through the foramina of Monro into the third 
ventricle, and then through the cerebral aqueduct into the fourth ventricle. CSF exits the 
ventricular system via the foramina of Luschka and the medial aperture of the foramina of 
Magendie into the cisterna magna. When CSF reaches the cortico-subarachnoid spaces and 
the spinal subarachnoid space, it gets absorbed by arachnoid granulations and drains into 
the venous sinuses, with small amounts of CSF being absorbed by spinal nerve roots.7 
According to the bulk flow model, the balance of CSF secretion and reabsorption 
establishes homeostasis in the ventricular system. 
The function of CSF hinges on three important properties: osmolarity, pressure, and 
flow.15,28 Osmolarity is established by the high rates of ion and water transport in the 
ventricular system.1,29,30 Osmolarity gradients established by ion pumps and 
macromolecule secretion drive continual CSF production facilitated by passive water 
channels in secretory epithelia.31-33 Enzymes and ion transport molecules critical to this 
process include carbonic anhydrase, the bumetanide-sensitive Na-K-2Cl cotransporter 
NKCC1, and aquaporin (AQP) water channels present in both the choroid plexus and 
ventricular ependymal cells.34-37 Changes in CSF osmolarity affect CSF volume and 
pressure, which are transduced by neuroepithelial mechanosensors and can significantly 
damage brain parenchymal tissue. CSF flow is key to the distribution of molecular signals 
and regulatory factors in the CNS.15 
CSF flow and ciliary function are intertwined in the ventricular system. Two types 
of cilia adorn the ventricular system: primary nonmotile cilia in monociliated cells, and 
motile cilia on multiciliated cells.38 Primary cilia, which can be found on embryonic and 
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adult neural progenitors15, function as sensory antennae to facilitate many signaling 
pathways, including sonic hedgehog (SHH), Wnt, and PDGFR-α pathways.39-42 These cilia 
also function as mechanosensors with the ability to detect the directional flow of CSF, 
transmitting signals to neural progenitors.43 Thus, monocilia allow cells to respond to 
developmental cues at several sites of neurogenesis in the CNS and are required for the 
normal development of neural progenitors. Motile cilia on multiciliated cells generate fluid 
flow from whip-like beating and are classically thought to facilitate CSF flow.44 However, 
the presence of CSF flow prior to the formation of motile cilia in zebrafish suggests that 
motile cilia may not be essential to CSF flow in embryonic stages.45 
Pathophysiology of Hydrocephalus 
Hydrocephalus is classically explained by the bulk flow model, which implies 
imbalance in CSF homeostasis as the root pathogenic cause for ventricular distention.1,46 
This homeostatic mechanism of an increase in CSF production relative to CSF reabsorption 
can manifest in two ways: (1) hypersecretion from the choroid plexus, or (2) obstruction to 
CSF flow at any point in the CSF conduit from the origin in the choroid plexus epithelium 
to the most distal point of absorption in the arachnoid granulations. Obstructive and 
hypersecretory mechanisms of hydrocephalus, often associated with high intracranial 
pressures (ICPs), are more common in secondary forms of hydrocephalus, especially when 
they arise from brain hemorrhage, tumor, or infection.6  
Certain observations of hydrocephalus are inconsistent with the bulk flow model: 
1) While congenital forms of hydrocephalus can present with high ICPs, others can have 
documented ICPs in the borderline-high, normal or even low range and can be associated 
with severe thinning of the cortical mantle;1 2) Functional arachnoid granulations are not 
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present in children younger than 2 years;47,48 3) CSF production is not restricted to the 
choroid plexus and can come from other ventricular sites;49 4) Experimental hydrocephalus 
can be induced by increasing intraventricular CSF osmolality;50 and 5) Hydrocephalus can 
also occur with increased in intraventricular fluid pulsation amplitudes alone without 
changes in flow or mean CSF pressures.51-53 
An alternate hydrodynamic model involving intracranial pulsations has been 
proposed to address some of the inconsistencies with the bulk flow model.52,54 Clearance 
of CSF has been shown to not only rely on unidirectional CSF flow but also on cardiac 
pulsatile movements. These pulsations direct CSF through the foramen magnum into the 
spinal arachnoid space and back into the skull into the brain parenchyma.55 In this model, 
arterial systolic pressure waves in the brain are normally dissipated by subarachnoid 
spaces, venous capacitance vessels, and intraventricular pulsations transmitted by the 
choroid plexus. Intraventricular pulsations are absorbed through the ventricular outlet 
foramina. Dysfunction of pulsation absorbers leads to abnormally high pulsation 
amplitude, resulting in ventricular expansion.1 Perturbations in pulsatile movements have 
been observed in human and murine models of hydrocephalus, but it is debated whether 
these perturbations are a cause or consequence of hydrocephalus.56 
Clinical Features of Hydrocephalus 
Hydrocephalus can be diagnosed by prenatal ultrasound, as early as 18 to 20 
gestational weeks.57 Detection of ventriculomegaly via ultrasound is often followed by 
studies such as a higher-level ultrasound scan, fetal MRI, TORCH screen (toxoplasmosis, 
rubella, cytomegalovirus, herpes simplex), or amniocentesis.58 Chorionic villus sampling 
or amniocentesis in known maternal carriers of L1CAM can diagnose X-linked 
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hydrocephalus.58 Hydrocephalus in infants manifests as abnormally increasing head 
circumference, irritability, vomiting, bulging of anterior fontanelle, and splaying of cranial 
sutures. In older children and adults, hydrocephalus can present with headache, vomiting, 
loss of developmental milestones, diplopia, and papilledema. 
Imaging remains the most important diagnostic tool and entails cranial ultrasonography 
(used to screen for ventriculomegaly patients with an open fontanel), MRI (used to map 
the anatomy and cause), and cine MRI CSF flow (used to track patient specific changes in 
CSF hydrodynamics).59-61 
Current Treatments 
Current mainstay therapies include surgical methods of CSF diversion, including 
CSF shunts and endoscopic third ventriculostomies. The most common type of shunt is the 
ventriculo-peritoneal shunt (VPS) which utilizes silastic tubing that runs subcutaneously 
from head to abdomen with a valve between the ventricular and distal catheters. Other 
types of shunts include ventriculo-atrial shunts and ventriculo-pleural shunts. Shunts often 
involve differential pressure settings or flow-regulating valve mechanisms with antisiphon 
or gravitational devices to prevent CSF overdrainage from posture related siphoning.1 
Another method of surgical diversion, the endoscopic third ventriculostomy, was 
developed in the 1990s for patients with non-communicating hydrocephalus and is now a 
routine procedure in the management of the condition.62 The endoscopic third 
ventriculostomy involves passing in a scope into the frontal horn of the lateral ventricle, 
then through the foramen of Monro into the third ventricle. An opening made in the floor 
of the third ventricle opens direct communication into the prepontine cistern. While the 
ETV proved to be an initial success in many patients, high rates of failure ensued, 
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especially in infants.63 Subsequently, choroid plexus cauterization (CPC) was added to 
ETV in an effort to decrease failure rates and improve efficacy.64 ETV and CPC was shown 
to have better results in children younger than one year compared to ETV alone.64-68 
Complications in the Acute Setting 
Shunt failure, often from mechanical obstruction, occurs in 40% of children within 
the first two years from original placement with continued risk of failure thereafter.13 The 
diagnosis of failure lies in imaging evidence such as increased ventricle size compared to 
baseline and in clinical symptoms such as headache, vomiting, irritability, decreased level 
of consciousness, and bulging fontanelle with accelerated head growth in infants. 
Shunt obstruction is treated with urgent surgery to identify and replace the 
obstructed component of the shunt, whether it is the proximal catheter, the distal catheter 
or the valve. In the case of more subtle symptoms such as chronic headache or deteriorating 
school performance, ICP monitoring can help establish obstruction as a cause. 
Perioperative mortality is low, while the estimated 30-year shunt-related mortality is 5-
10%.69,70 
Shunts infections can occur at a rate of 5 to 9% per procedure mostly within three 
months71-73 and can present with fever, irritability, wound erythema, or symptoms of shock 
malfunction. A CSF culture from shunts can elucidate the pathogen. Infection can also 
present within abdominal system from a peritoneal CSF pseudocyst.74 In cases of infection, 
systematic prophylactic antibiotics as well as standardized surgical protocols are utilized 
for management.72,75 Another complication for shunts includes overdrainage, which can 
present with subdural hygroma or hematoma.76 In these cases, slit-like syndrome develops 
with a ventricle size of small and accompanies low pressure headaches for acute 
 8 
intermittent symptoms of shunt obstruction. Treatment schemes may include shunt revision 
to reduce CSF drainage, shunting lumbar CSF space, and cranial vault expansion. 
ETV failure generally occurs at an incidence of about 35%.77 However, success is 
dependent on individual prognostic factors including aging cause of hydrocephalus.63 In 
this regard it is quantified by the ETV success score.63,78 Most failures occur within the 
first six months of surgery63,79,80, but the failure rate relative to shunts decreases after 2-3 
years.77 Other rare complications include basilar artery injury, permanent endocrinopathy, 
hypothalamic injury or other brain injury, and perioperative mortality.81 
Clinical Outcomes in the Long-Term 
The degree of long-term cognitive dysfunction in hydrocephalus is linked to the brain 
dysmorphology or primary injury associated with the causal mechanisms of the disorder. 
Hydrocephalus is accompanied by impairment in overall intelligence, verbal IQ, spatial 
navigation, executive function, learning, memory, and processing speed.82-87 In 20% of 
patients, a near-normal quality of life is maintained88; however other children have 
significant impediments to quality of life. Epilepsy develops in as many as 34% of patients 
treated with shunting in infancy.89 Headaches are frequently reported in shunted 
hydrocephalus, with 10-20% reporting severe headaches in children88, and 40% reporting 
chronic headaches in adults90. Depression treatment was reported in 45% of patients, care 
dependence in 43%, and unemployment in 43%.91 
Etiologies of Hydrocephalus 
Here I will characterize broad categories of the etiologies of human hydrocephalus 
including structural causes, inflammatory processes, vascular dysfunction, and 
dysregulated iron and water transport. 
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Structural causes 
Hydrocephalus can arise from structural brain conditions in patients, including 
myelomeningocele, Chiari II malformation, Dandy-Walker complex, and encephalocele. 
These syndromes can often entail ependymal denudation and subcommisural organ 
dysfunction leading to closure of the fetal aqueduct.92 Mass lesions can also obstruct CSF 
pathways at the cerebral aqueduct or fourth ventricle. These lesions include developmental 
cysts and various tumors. Tectal gliomas and other posterior third ventricle tumors can 
obstruct the aqueduct, while common pediatric posterior fossa brain tumors such as 
cerebellar astrocytomas, medulloblastomas, and ependymomas can obstruct the outlets of 
the fourth ventricle.1 
Inflammatory processes 
Infection and hemorrhage can result in inflammation of the meninges or ventricles, 
inducing hydrocephalus via impairment of CSF circulation and absorption of the normal 
dampening of arterial pulsations. In developed countries, intraventricular hemorrhage of 
prematurity is one of the most common causes of acquired hydrocephalus.13 In Uganda and 
other sub-Saharan African countries, neonatal ventriculitis with a climate-associated 
cyclical incidence pattern of infection is a major cause of acquired postinfectious 
hydrocephalus.93 Ventricular inflammation induces ependymal scarring, intraventricular 
obstruction, and multi-compartmental hydrocephalus. In addition, hydrocephalus can arise 
from the inhibition of ependymal ciliary development and function in fetal ventriculitis, or 





Idiopathic venous outflow resistance, venous sinus collapse96,97, venous 
thrombosis98, and venous outlet stenosis at the skull base associated with cranial facial 
dysostoses such as Crouzon’s and Pfeiffer’s syndromes99, are all causes of reduced venous 
compliance, and can be a primary cause of communicating hydrocephalus. Cerebral 
hyperaemia has also been documented in cases of idiopathic infant hydrocephalus.100 
Dysregulated Iron and Water Transport 
Aberrant ion and water transport processes in the choroid plexus and ventricular 
system have been implicated in hydrocephalus.36,101-104 For example, CSF hypersecretion 
from choroid plexus hyperplasia and non-obstructive tumors of the choroid plexus have 
been linked to hydrocephalus.[50] Recently, a recessive genotype in ATP1A3 encoding the 
α3 subunit of the Na+/K+ ATPase was identified in a human case of hydrocephalus.105 In 
addition, mice with knockout of aquaporin water channel AQP4 have been shown to 
develop obstruction of the aqueduct. [44] Conversely, the upregulation of ependymal 
AQP4 in late rather than early stages of hydrocephalus suggests a compensatory role for 
the channel in the maintenance of water homeostasis.106,107 
Another system that may contribute to the development of hydrocephalus is the 
glymphatic system, a paravascular system that facilitates water and solute movement from 
subarachnoid CSF into brain interstitial fluid and out through the deep draining veins.108,109 
Notably, the glymphatic system contains paravascular channels bounded by astrocytic 




Secondary Effects of Hydrocephalus 
The damaging consequences of hydrocephalus lie in the effects of increased ICP and 
ventriculomegaly. Neurovascular damage and inflammation secondary to increased ICP 
and ventriculomegaly yield tissue injury that compromises brain development.92,111 In the 
acute stage of ventriculomegaly, compression stretch of the periventricular tissue including 
axons, myelin, and microvessels leads to ischemia, hypoxia, inflammation, and increased 
CSF pulsatility.92 The chronic stage of ventriculomegaly entails gliosis, demyelination, 
axonal degeneration, periventricular edema, metabolic impairments, and changes to the 
permeability of the blood brain barrier.92 Hydrocephalus can be exacerbated by ependymal 
denudation, in which the exposure of the sensitive SVZ to toxic metabolites compromises 
neurogenesis.112,113 
Genetic Mechanisms of Congenital Hydrocephalus and the Significance of Next-
Generation Sequencing in Neurodevelopmental Disorders 
While there is growing evidence of multiple genetic determinants underlying syndromic 
and non-syndromic forms of hydrocephalus, the genetic and molecular architecture of 
neurodevelopmental disorders have historically been difficult to study given their complex, 
highly heritable, and polygenic natures.114,115 Population studies have revealed familial 
aggregation of congenital hydrocephalus, increased recurrent risk ratios for same sex twins 
and first-degree or second-degree relatives.116,117 Several loci and genes have been linked 
to non-syndromic forms of CH in animals and syndromic forms of hydrocephalus in 
humans.2,7,118,119 Over 100 genes are implicated in these human cases of syndromic 
hydrocephalus, which entail severe systemic abnormalities (e.g. respiratory, cardiac, and 
renal) and implicate several biological pathways in the development of hydrocephalus (e.g. 
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neuronal adhesion, Wnt signaling pathway, vesicle trafficking, dystroglycanopathies, 
ciliopathies, neural tube defects, planar cell polarity, RASopathies, PIK3-AKT-MTOR 
pathways, and growth factor signaling).7 Yet, very few causal mutations have been 
identified in human non-syndromic hydrocephalus, despite epidemiological studies and 
reports of familial CH suggesting genetic etiologies for up to 40% of cases.120 Traditional 
linkage and targeted sequencing approaches have identified mutations in L1CAM (OMIM# 
307000), MPDZ (OMIM# 615219), CCDC88C (OMIM# 236600), and AP1S2 (OMIM# 
300629).7 The sporadic nature of >95% of CH cases limits the utility of traditional genetic 
approaches,7 and the heterogeneity in approaches for gene discovery coupled with the wide 
range of cellular processes altered by these genes confounds efforts to formulate a uniform 
paradigm of CH pathophysiology. 
In this regard, next-generation sequencing has revolutionized the identification of 
genetic causes of human disease. Whole exome sequencing (WES) in particular proves to 
be a powerful unbiased strategy for gene discovery.5 WES can identify both inherited 
genetic variants in familial pedigrees and de novo mutations (DNMs) in parent-offspring 
trios.121 WES of the trio design relies on a simple genetic model, in which the causative 
mutation of a condition is assumed to be present in the affected child but absent in the 
unaffected parents. The occurrence of DNMs in the same gene in unrelated individuals 
implies a potential pathogenic contribution to the disease. Thus, WES of large patient 
cohorts can identify genes mutated in affected subjects more often than expected by 
chance. 
The advent of next-generation sequencing methods has led to widespread discovery 
of multiple genetic determinants of neurodevelopmental disorders, including autism122-124, 
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craniosynostosis125, epilepsy126, brain malformations127, and other severe, undiagnosed 
developmental disorders128. While these candidate genes provide molecular clues for 
pathogenesis, locus heterogeneity and biological pleiotropy complicates our ability to 
predict how these genetic alterations affect the inherently complex biological pathways of 
brain development.129 
One solution in translating genetic findings to a higher-level mechanistic insight 
lies in the identification of pathways that mark convergence of the biological activity of 
genes conferring high risk for a particular condition. To that end, transcriptomic mapping 
with RNA-seq allows for the investigation of gene expression patterns in the developing 
human brain, an approach termed “integrative genomics”. Given the likelihood that genetic 
perturbations involved in a disorder are likely to have converging pathways129, WES 
genetic variants are integrated with human transcriptomes to determine points of 
convergence in developing brain regions, developmental periods, gene co-expression 
networks, and individual cell types. 
In a pioneering study using BrainSpan, a spatio-temporal transcriptomic atlas of the 
developing human brain (from embryonic to late adulthood stages)130, ASD-associated 
variants converge in cortical glutamatergic projection neurons during the midfetal 
period.131 Using the same transcriptomic atlas, another study found that ASD-associated 
genes coalesce in modules, or co-expression networks identified via weighted gene co-
expression network analysis (WGCNA).132 These modules are characterized by distinct 
biological functions, such as early transcriptional regulation and synaptic development.133 
Importantly, these studies leveraged co-expression networks to construct a spatio-temporal 
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map of ASD risk gene expression, identifying mid-fetal glutamatergic projection neurons 
as a point of convergence with potential disease implications.131,133  
In a recent study, Satterstrom et al. provided further evidence for the role of ASD 
risk genes in early brain development and excitatory-inhibitory neuron imbalance.124 By 
examining risk gene enrichment in a single-cell RNA-seq dataset from prenatal human 
forebrain134, this study demonstrated that ASD genes are most strongly enriched in early 
excitatory neurons and striatal interneurons, thus implicating maturing and mature neurons 
of both excitatory and inhibitory lineages.124 Taken together, these studies highlight the 
power of integrative genomic approaches for elucidating the spatiotemporal dynamics and 
significance in early brain development of risk genes of a given disorder. 
I now present findings from the largest WES study to date of sporadic, 













V. Statement of Purpose 
With the purpose of gaining better insight into the pathogenesis of CH, the goal of 
this study is to elucidate the genetic and molecular architecture of CH through the 
integration of gene discovery from the largest whole-exome sequenced CH cohort with 
transcriptional networks (modules) and cell-type markers from the latest transcriptomic 
atlases of the mid-gestational human brain to uncover the genomic and molecular 
architecture of CH. Thus, I present my findings from my project with the following specific 
aims: 
Specific Aim 1: Establishing a large and deeply phenotyped CH patient cohort. 
In this aim, we will establish a CH patient cohort with an innovative and 
collaborative social-media recruitment platform. Probands that satisfy our inclusion criteria 
demonstrate: 1) the diagnosis of primary CH (i.e., not due to secondary or syndromic 
causes); 2) no documentation of L1CAM mutation; and 3) the availability of both biological 
parents to contribute DNA. Probands are actively recruited from Yale School of Medicine 
(YSM) and our collaborating institutions (Boston Children’s Hospital, USA; CURE 
Hospital, Uganda; Marmara Hospital, Turkey). We will also employ a unique social media 
recruitment strategy utilizing Facebook, approved by the Yale University IRB/HIC 
(Kristopher Kahle, PI; HIC/HSC Protocol#: 1602017144), which allows us to efficiently 
identify and rapidly obtain DNA from CH patients around the world using mailed consent 
forms and buccal swab kits. We place emphasis on collecting DNA from children with 
severe cases of CH that have undergone treatment, and families with multiple affected 
members. For each index case, we obtain full medical records, prior clinical genetic testing, 
and importantly, full brain MRIs and neuroradiology reports. 
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Specific Aim 2: Identification of novel CH-causing genes using whole exome capture 
and massively parallel DNA sequencing. 
In this aim, we will utilize WES and bioinformatics to identify novel CH-causing 
mutations. All trios are sequenced at the Yale Center for Genome Analysis (YCGA). 
Resulting sequence is analyzed with computational pipelines that enable the rapid 
identification of rare/novel/de novo variants which are predicted to alter the function of the 
encoded protein, are specific for the disease, and are not detected in published and internal 
reference SNV sequence databases of unaffected patients.135 Assuming that there are single 
loci accounting for the majority of remaining heritability, we predict WES will detect 
several novel CH genes. We predict genes may cluster in pathways relevant for 
neurodevelopment. We anticipate it will be possible to identify multiple independent 
mutations in the same genes or genetic pathways in different individuals with similar 
phenotypes. 
Specific Aim 3: Identification of gene co-expression networks and cell types pertinent 
to CH risk genes from transcriptomic atlases of the developing human brain. 
In this aim, we will harness two previously published transcriptomic atlases of the 
mid-gestational human brain: a bulk RNA-seq atlas characterized by WGCNA modules, 
and a single cell (sc)RNA-seq atlas characterized by cell type markers. We will test for 
enrichment of cohort-determined risk genes as well as known syndromic genes of 
hydrocephalus in these modules and cell type markers to identify biological points of 
convergence from genotype to phenotype. We will also test the enrichment of risk genes 
for autism spectrum disorder (ASD) and developmental disorders (DD) for comparison 
between biological pathways of CH and other neurodevelopmental disorders. 
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All study procedures and protocols comply with Yale University’s Human 
Investigation Committee and Human Research Protection Program. Written informed 
consent for genetic studies was obtained from all participants. Inclusion criteria included 
patients with primary CH who did not carry a genetic diagnosis before surgical treatment 
or inclusion in the study. Subjects with either a known chromosomal aneuploidy or a copy-
number variation with known association to CH were also excluded. Hydrocephalus cases 
with secondarily acquired etiologies such as intraventricular hemorrhage, meningitis or 
other central nervous system infection, obstruction due to tumors or cysts and stroke were 
excluded. Children with hydranencephaly, large cysts and cephaloceles, 
myelomeningocele (Chiari II malformation) or benign extra-axial CSF accumulation 
(benign external hydrocephalus) were also excluded. Sequenced trios were composed of 
381 primary CH probands including 232 parent–offspring trios and 149 singletons 
(Supplementary Tables 1 and 2). All probands had undergone surgery for therapeutic 
CSF diversion (shunt placement and/or endoscopic third ventriculostomy). Patients and 
participating family members provided buccal swab samples (Isohelix SK-2S DNA buccal 
swab kits), medical records, neuroimaging studies, operative reports and CH phenotype 
data. 
Controls consisted of 1,798 unaffected siblings of people with ASD and unaffected 
parents from SSC.136 Only the unaffected siblings and parents, as designated by SSC, were 
included in the analysis and served as controls for this study. Permission to access to the 
genomic data in the SSC on the National Institute of Mental Health Data Repository was 
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obtained. Written informed consent for all participants was provided by the Simons 
Foundation Autism Research Initiative. 
Whole-exome sequencing and variant calling 
Exon capture was performed on genomic DNA samples derived from saliva or 
blood using Roche SeqCap EZ MedExome Target Enrichment kit or IDT xGen target 
capture kit followed by 101 or 148 base-paired-end sequencing on the Illumina platforms 
as described previously.137,138 Sequence reads were aligned to the human reference genome 
GRCh37/hg19 using BWA-MEM. Single-nucleotide variants and small indels were called 
using a combination of GATK HaplotypeCaller139,140 and Freebayes141 and annotated using 
ANNOVAR142. Allele frequencies were annotated in the Exome Aggregation Consortium, 
gnomAD (v.2.1.1) and Bravo databases.143,144 MetaSVM and MPC algorithms were used 
to predict deleteriousness of missense variants (D-Mis, defined as MetaSVM-deleterious 
or MPC-score ≥2).145,146 Inferred LoF variants consisted of stop-gain, stop-loss, frameshift 
insertions/deletions, canonical splice site and start-loss. LoF and D-Mis mutations were 
considered ‘damaging’. PCR amplicons containing the mutation verified mutations in 
genes of interest. 
DNMs were called using TrioDeNovo.147 Candidate DNMs were further filtered 
based on the following criteria: (1) exonic or splice-site variants; (2) read depth (DP) of 10 
in the proband and both parents; (3) minimum proband alternative read depth of 5; (4) 
proband alternative allele ratio ≥28% if having <10 alternative reads or ≥20% if having 
≥10 alternative reads; (5) alternative allele ratio in both parents ≤3.5%; and (6) global 
MAF ≤ 4 × 10−4 in the Exome Aggregation Consortium database. 
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For recessive variant analysis, we filtered for rare (MAF ≤ 1 × 10−3 in Bravo and in-
cohort MAF ≤ 5 × 10−3) homozygous and compound heterozygous variants that exhibited 
high-quality sequence reads (pass GATK variant quality score recalibration, ≥4 total reads 
total for homozygous and ≥8 reads for compound heterozygous variants, genotype quality 
(GQ) score ≥10 for homozygous and GQ score ≥20 for compound heterozygous variants). 
Only LoF, D-Mis and nonframeshift indels were considered potentially damaging to the 
disease. For probands whose parents’ WES data were not available, only homozygous 
variants were analyzed. 
For rare heterozygous variants, only LoF and D-Mis mutations were considered to 
be potentially disease associated and were filtered using the following criteria: (1) pass 
GATK variant quality score recalibration; (2) MAF ≤ 5 × 10−5 in Bravo and in-cohort 
MAF ≤5 × 10−3; (3) DP ≥8 independent reads; and (4) GQ score ≥20. RGs and DNMs were 
excluded. 
After filtering using the aforementioned criteria for each type of mutation, in silico 
visualization was performed to remove false-positive calls. Variants in the top candidate 
genes were further confirmed by Sanger sequencing. 
Quantification and statistical analysis 
DNM expectation model 
Because the CH trios were captured by two different reagents (MedExome and 
IDT), we took the union of all bases covered by different capture reagents and generated a 
Browser Extensible Data file representing a unified capture for all trios. We used bedtools 
(v.2.27.1) to extract sequences from the Browser Extensible Data file.148 We then applied 
a sequence context-based method to calculate the probability of observing a DNM for each 
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base in the coding region, adjusting for sequencing depth in each gene as described 
previously.149 Briefly, for each base in the exome, the probability of observing every 
trinucleotide mutating to other trinucleotides was determined. ANNOVAR (v2015Mar22) 
was used to annotate the consequence of each possible substitution. RefSeq was used to 
annotate variants (based on the file ‘hg19_refGene.txt’ provided by ANNOVAR). For each 
gene, the coding consequence of each potential substitution was summed for each 
functional class (synonymous, missense, canonical splice site, frameshift 
insertions/deletions, stop-gain, stop-loss and start-lost) to determine gene-specific mutation 
probabilities.149 The probability of a frameshift mutation was determined by multiplying 
the probability of a stop-gain mutation by 1.25, as described previously.149 In-frame 
insertions or deletions are not accounted for by the model and were not considered in the 
downstream statistical analyses. To align with ANNOVAR annotations, analysis was 
limited to variants that were located in the exonic or canonical splice site regions and were 
not annotated as ‘unknown’ by ANNOVAR. Following the inclusion criteria, we identified 
potential coding mutations and generated gene-specific mutation probabilities for 19,347 
unique genes. Owing to the difference in exome capture kits, DNA sequencing platforms 
and variable sequencing coverage between case and control cohorts, separate de novo 
probability tables were generated for cases and controls, respectively. 
Estimation of expected number of rare transmitted variants 
We implemented a multivariate regression model to quantify the enrichment of rare 
transmitted variants in a specific gene or gene set in cases, independent of controls. 
Additional details about the modeling of the distribution of recessive and transmitted 
heterozygous variant counts are described in our recent study.150 
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De novo enrichment analysis 
The burden of DNMs in CH cases and unaffected ASD controls was determined 
using the denovolyzeR package151 as previously described150. Briefly, the expected number 
of DNMs in case and control cohorts across each functional class was calculated by taking 
the sum of each functional class-specific probability multiplied by the number of probands 
in the study 2× (diploid genomes). Then, the expected number of DNMs across functional 
classes was compared to the observed number in each study using a one-tailed Poisson 
test.149 Gene set enrichment analyses only considered mutations observed or expected in 
genes within the specified gene set (high brain-expressed, LoF-intolerant). 
To examine whether any individual gene contains more protein-altering DNMs 
than expected, the expected number of protein-altering DNMs was calculated from the 
corresponding probability adjusting for cohort size. A one-tailed Poisson test was then used 
to compare the observed DNMs for each gene versus expected. As separate tests were 
performed for protein-altering, protein-damaging and LoF DNMs, the Bonferroni multiple-
testing threshold is, therefore, equal to 8.6 × 10−7 (= 0.05 / (3 tests × 19,347 genes)). 
To estimate the number of genes with multiple DNMs, one million permutations 
were performed to derive the empirical distribution of the number of genes with multiple 
DNMs. For each permutation, the number of DNMs observed in each functional class was 
randomly distributed across the genome adjusting for gene mutability. The empirical p-
value was calculated as the proportion of times that the number of recurrent genes from the 
permutation equals or exceeds the observed number of recurrent genes as follows: 
 







Enrichment analysis for dominant and recessive variants 
We implemented a polynomial regression model coupled with a one-tailed 
binomial test to quantify the enrichment of damaging RGs in a specific gene or gene set in 
cases and controls, separately as described previously.150 The expectation of the RG count 
for each gene was calculated by the formula below: 





where ‘i’ denotes the ‘ith’ gene and ‘N’ denotes the total number of RGs. For a given gene 
set, the expected RG count was based on the sum of fitted values for the gene set. 
 
Expected RG𝐺𝑒𝑛𝑒 𝑆𝑒𝑡 = 𝑁 ×
∑ Fitted𝐺𝑒𝑛𝑒 𝑆𝑒𝑡 value
∑ Fitted value𝐺𝑒𝑛𝑒𝑠
 
For rare damaging or LoF heterozygous variants, we found that the number of 
damaging or LoF heterozygous variants in a gene was inversely correlated with the pLI 
score obtained from the gnomAD database. To control for the potential confounding effect 
due to the pLI score, we stratified genes into five subsets by pLI quartiles: (i) those with a 
pLI score between 0 and the first quantile (6.4x10-8); (ii) those with a pLI score between 
the first quantile and the second quantile (pLI = 1.9x10-3); (iii) those with a pLI score 
between the second quantile and the third quantile (pLI = 0.48); (iv) those with a pLI score 
between third quantile and 1; (v) those without a pLI score. For each set, the expected 
number of damaging or LoF heterozygous variants for a gene was estimated by the 
following formula: 





where ‘j’ denotes the ‘jth’ gene, ‘k’ denotes the ‘kth’ set, and ‘L’ denotes the total number 
of damaging or LoF heterozygous variants. 
Case–control burden analysis 
Case and control cohorts were processed using the same pipeline and filtered with 
the same criteria. A one-sided Fisher’s exact test was used to compare the observed number 
of total alternative alleles, regardless of the transmission pattern in cases to controls in the 
gnomAD (without disease-enriched TOPMed samples) database. 
Determining gene lists 
The gene lists used for recessive enrichment analysis were curated as below. The 
mH genes were compiled by the association of their disease model, disease ortholog or 
phenotype with hydrocephalus per MGI (http://www.informatics.jax.org/). The 
dystroglycanopathies genes and ciliopathies genes were compiled by Kousi and Katsanis.7 
Cell adhesion molecules, synaptic vesicle cycle, Ras signaling pathway, Wnt signaling, 
PI3K–ATK–mTOR pathway, and lysosomal storage disorder gene sets were curated based 
on KEGG and pathway database and the HUGO Gene Nomenclature Committee. A planar 
cell polarity gene list was curated based on Wang et al.152 and Tissir and Goffinet153. 
Gene lists from transcriptomic analyses were curated as below. Risk genes from 
our CH cohort were defined as genes that harbored ≥1 inherited heterozygous LoF mutation 
of genome-wide significance, genes intolerant to LoF mutations (pLI > 0.9) with ≥1 LoF 
DNM and genes intolerant to missense mutations (mis-Z > 2) with ≥1 missense DNM. 
These genes were categorized as high confidence if they harbored ≥1 inherited 
heterozygous LoF mutation of genome-wide significance or ≥2 protein-altering DNMs; 
and as probable risk if they harbored 1 protein-altering DNM. This yielded a high 
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confidence set of 9 hydrocephalus genes (TRIM71, PTEN, PIK3CA, SMARCC1, FMN2, 
MTOR, FOXJ1, PTCH1 and FXYD2) and a probable set of 55 genes. 
We assembled lists of genes previously known to cause isolated and syndromic 
forms of hydrocephalus in humans from three publications: Kousi and Katsanis 
summarized over 100 genes described in known hydrocephalus syndromes7, Furey et. al. 
outlined new genes implicated in CH through WES137, and Shaheen et. al. summarized 
genes with recessive mutations linked to familial forms of CH154. 
We compiled a list of genes with rare risk variation in ASD from two papers: Ruzzo 
et. al.123, which describes genes harboring rare inherited variants and Satterstrom et. al.124, 
which describes genes with de novo variants and case–control variation. We compiled a 
list of developmental disorder (DD) risk genes from DDD 2017128, which describes genes 
enriched in damaging DNMs. 
Module enrichment 
Module gene lists were obtained from a bulk RNA-seq atlas from of the 
midgestational human prenatal cortex (14–21 gestational weeks).155 WGCNA156 of this 
atlas identified modules (labeled by color) of genes that share highly similar expression 
patterns during midgestational cortical development.155 In a background set of all genes 
categorized in coexpression modules, we used a logistic regression for an indicator-based 
enrichment: is.disease ~ is.module + gene covariates (GC content, gene length and mean 
expression in bulk RNA-seq atlas), as described previously.155 Of the 18 WGCNA 
modules, the gray module, by WGCNA convention157, contains all genes that do not 
coexpress and are consequently unassigned to a coexpression network. Thus, the gray 
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module was excluded from enrichment testing and enrichment significance was defined at 
the Bonferroni multiple-testing cutoff (α = 0.05 / 17 = 2.94 × 10−3). 
Module GO and HP profiling 
We used g:GOSt from g:Profiler, a tool for functional profiling of gene lists, to 
obtain descriptive terms for enriched modules.158 We used all annotated genes as the 
statistical domain scope, the g:SCS algorithm to address multiple testing and P = 0.05 as a 
user-defined threshold for statistical significance. For each gene list, we retained terms of 
100–1,000 genes and we plotted the top 20 enriched terms from GO biological process 
annotations and the top 20 enriched terms from HP ontology annotations. 
Cell type enrichment 
Cell-type-enriched genes (cell type markers), were obtained from a scRNA-seq 
atlas that maps the human midgestational cortex (17–18 gestational weeks).159 In a 
background set of all genes expressed in ≥3 cells of the scRNA-seq atlas, we used a logistic 
regression for indicator-based enrichment: is.cell.type ~ is.disease + gene covariates (GC 
content, gene length). Enrichment significance was defined at the Bonferroni multiple-
testing cutoff (α = 0.05 / 16 = 3.13 × 10−3). 
Overlap analysis 
As described previously150, permutation test was performed to assess the 
enrichment of overlapping genes with either damaging (D-mis + LoF) or LoF DNMs 
shared between CH and four other trio-based cohorts: autism, developmental disorder, 
idiopathic cerebral palsy, and congenital heart disease. Given the observed numbers of 
genes with DNMs in the CH and other cohorts as 𝑁1 and 𝑁2, respectively, and the observed 
number of overlapping genes as 𝑀, we sampled 𝑁1 genes from all genes in the CH cohort 
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and 𝑁2 genes from all genes in the autism cohorts without replacement using the probability 
of observing at least one DNM as weight. The number of overlapping genes, 𝑃, was 
determined in each interaction of the simulation. A total of 1,000,000 iterations were 
conducted to construct the empirical distribution. The empirical number of overlapping 
genes was calculated by taking the average of the number of overlapping genes across all 
iterations. The empirical 𝑃 value was calculated as follows: 
𝐸𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙 𝑃 𝑣𝑎𝑙𝑢𝑒 =  
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We recruited 381 genetically undiagnosed probands (including 232 parent–
offspring trios) with sporadic, neurosurgically treated, primary (developmental) CH 
(excluding myelomeningocele) (Supplementary Table 1), including 169 previously 
reported CH probands with 125 trios137. Studies were Institutional Review Board (IRB)-
approved by Yale’s Human Research Protection Program (Methods). DNA was isolated 
and WES was performed.137 A total of 1,798 control trios (comprising unaffected siblings 
and parents of patients with autism spectrum disorder (ASD) from the Simons Simplex 
Collection (SSC) cohort) were analyzed in parallel (Supplementary Tables 2 and 3). 
Overall, 8.7% of probands were from consanguineous union, versus 1.3% ASD sibling 
controls (Supplementary Table 2; Methods for sequence variant calling, calibration, 
annotation and validation). Mutations in known familial CH genes7 accounted for ~2.1% 
of cases, including mutations in L1CAM (OMIM no. 307000), MPDZ (OMIM no. 615219), 
FLNA (OMIM no. 300049) and CRB2 (OMIM no. 219730) described in Supplementary 
Table 4. Removal of the eight patients from further analyses yielded 373 CH probands, 
including 225 trios. 
Protein-damaging de novo mutations account for a large fraction of sporadic CH 
The average de novo mutation (DNM) rate of 1.307 per subject resembled previous results 
with the identical sequencing platform138 and followed a Poisson distribution 
(Supplementary Fig. 1). Protein-damaging DNMs were significantly enriched among all 
genes (enrichment of 1.72, P = 6.6 × 10−7; Supplementary Table 5), with greater 
enrichment among genes intolerant of loss-of-function (LoF) mutations (pLI ≥ 0.9 in 
gnomAD v.2.1.1) and among genes in the top quartile of mouse brain bulk RNA-
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sequencing (RNA-seq) expression (Methods). Enrichment was greatest among genes 
meeting both criteria (3.71-fold, P = 5.0 × 10−9; Supplementary Table 5). We estimated 
that damaging DNMs can account for 17.7% of cases in this cohort (Supplementary Table 
5). 
Twelve genes had ≥2 protein-altering DNMs (Table 1a) versus 2.7 genes expected 
by chance (4.5-fold enrichment; P = 8.0 × 10−6 by 1 million permutations; Table 1b). 
Greater enrichment of recurrent genes was observed in LoF-intolerant genes with multiple 
DNMs (8.9-fold enrichment; P = 1.0 × 10−5; Table 1c), supporting these as causal CH 
disease genes. Five genes (TRIM71, SMARCC1, PTEN, PIK3CA and FOXJ1) had 
significantly more protein-altering DNMs than expected by chance (P value threshold of 
8.6 × 10−7 after correction for testing 19,347 RefSeq genes in triplicate using a one-tailed 
Poisson test; Table 1a). Three other genes that are highly intolerant of LoF mutations 
exhibited ≥2 protein-altering DNMs: MTOR, PTCH1 and FMN2. Mutations in these 
cohort-determined risk genes (TRIM71, SMARCC1, PTEN, PIK3CA, FOXJ1, MTOR, 










Table 1: Genes with multiple DNMs are candidate CH risk genes 
A. Genes with ≥2 protein-altering DNMs 
Gene # LoF # D-mis # T-mis Poisson P-value pLI mis_z 
TRIM71 0 6 0 2.4x10-16 1.00 3.28 
PTEN 2 1 0 1.9x10-8 0.26 3.49 
SMARCC1 2 1 0 2.0x10-8 1.00 2.45 
FOXJ1 2 0 0 1.4x10-7 0.97 0.70 
PIK3CA 0 1 2 4.9x10-7 1.00 5.60 
PTCH1 2 0 0 3.0x10-6 1.00 1.68 
PLOD2 0 2 0 1.6x10-5 0.00 0.56 
SGSM3 0 0 2 1.0x10-4 0.00 0.16 
LRIG1 1 0 1 1.7x10-4 0.04 -1.18 
FMN2 1 0 1 4.4x10-4 1.00 0.32 
MTOR 0 1 1 9.1x10-4 1.00 7.02 
MUC17 0 0 2 1.3x10-3 0.00 -7.83 
(A) Twelve genes with more than 1 protein-altering DNMs found in cases. P-values 
are calculated using the one-tailed Poisson test comparing the observed number of 
DNMs for each gene versus expected. As separate tests were performed for protein-
altering, protein-damaging, and LoF DNMs, the Bonferroni multiple-testing 
threshold is equal to 8.6x10-7 (=0.05/[3 tests*19,347 genes]). The most significant 
p-value of the three tests was reported. pLI and mis-z values are based on gnomAD 
v2.1.1. 
B. Genes with multiple DNMs in 225 cases (observed vs expected) 
  Observed Expected Enrichment P-value 
Syn 0 0.18 0 1 
Missense 6 1.86 3.23 0.01 
D-mis 2 0.29 7.01 0.03 
LoF 4 0.08 48.38 3.0x10-6 
Protein-
damaging 
6 0.85 7.08 1.3x10-4 
Protein-
altering 
12 2.66 4.5 8.0x10-6 
(B) More genes with multiple DNMs were detected in 225 case trios than expected 
by chance, as shown by the observed numbers of genes with > 1 DNM in each 
variant category. 1 million simulations were performed, based on the per-base 
probability of mutations in each category, to determine the likelihood and the 
expected number of genes with > 1 DNM.  
C. LoF-intolerant genes with multiple DNMs in 225 cases (observed vs expected) 
  Observed Expected Enrichment P-value 
Syn 0 0.05 0 1 
Missense 3 0.54 5.52 0.02 
D-mis 1 0.12 8.2 0.12 
LoF 3 0.02 121.02 2.0x10-6 
Protein-
damaging 
4 0.36 11.03 4.5x10-4 
Protein-
altering 
7 0.79 8.9 1.0x10-5 
(C) Greater enrichment than expected by chance was observed when restricting 
analysis to LoF-intolerant genes (N = 3,049) with multiple DNMs in 225 case trios.  
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D. LoF-tolerant genes with multiple DNMs in 225 cases (observed vs expected) 
  Observed Expected Enrichment P-value 
Syn 0 0.13 0 1 
Missense 3 1.31 2.28 0.14 
D-mis 1 0.16 6.12 0.15 
LoF 1 0.06 17.27 0.06 
Protein-
damaging 
2 0.48 4.12 0.08 
Protein-
altering 
5 1.88 2.66 0.04 
(D) Restricting analysis to genes tolerant to LoF mutations showed marginal 
enrichment for genes with multiple protein-altering mutations. 
D-mis: Damaging missense mutations; T-mis: Tolerated missense mutations; 




































Fig. 1: De novo, transmitted, and unphased mutations in TRIM71. 
 
 
a, Pedigrees and sequencing electropherograms of Sanger sequencing depict all TRIM71 mutations in genomic DNA 












Fig. 2: De novo, transmitted, and unphased mutations in SMARCC1. 
 
a, Pedigrees and sequencing electropherograms of Sanger sequencing depict all SMARCC1 mutations in genomic DNA 









Fig. 3: De novo, transmitted, and unphased mutations in PIK3CA. 
 
a, Pedigrees and sequencing electropherograms of Sanger sequencing depict all PIK3CA mutations in genomic DNA 
















Fig. 4: De novo, transmitted, and unphased mutations in PTEN. 
 
a, Pedigrees and sequencing electropherograms of Sanger sequencing depict all PTEN mutations in genomic DNA 



















Fig. 5: De novo, transmitted, and unphased mutations in MTOR. 
 
a, Pedigrees and sequencing electropherograms of Sanger sequencing depict all MTOR mutations in genomic DNA 
















Fig. 6: De novo and transmitted mutations in FOXJ1. 
 
a, Pedigrees and sequencing electropherograms of Sanger sequencing depict all FOXJ1 mutations in genomic DNA 

























Fig. 7: De novo and transmitted mutations in FMN2. 
 
 
a, Pedigrees and sequencing electropherograms of Sanger sequencing depict all FMN2 mutations in genomic DNA 
from CH probands. b, Representative T1 or T2-weighted brain magnetic resonance images for all available probands. c, 

















Fig. 8: De novo, transmitted, and unphased mutations in PTCH1. 
 
 
a, Pedigrees and sequencing electropherograms of Sanger sequencing depict all PTCH1 mutations in genomic DNA 








Notably, animal and pre-clinical evidence suggests that mutations in these cohort-
determined CH risk genes disrupt NSC regulation (Supplementary Table 11). TRIM71, 
encoding the RNA-binding protein Tripartite Motif Containing 71, homolog of let-7 (lethal 
7) microRNA target lin-41, maintains stem cell pluripotency by the post-transcriptional 
silencing of target mRNAs via interactions with its RNA-binding NHL domain.160 Trim71 
deletion in mice results in exencephaly and embryonic lethality by decreasing NSC 
proliferation.160 SMARCC1, encoding BAF155 subunit of BRG1/BRM-associated factor 
(BAF; Saccharomyces cerevisiae SWI/SNF) chromatin remodeling complex, is an ATP-
dependent chromatin remodeler that regulates gene expression required for NSC 
proliferation, differentiation and survival during telencephalon development.161 
Approximately 80% of mice homozygous for Smarcc1 missense allele Baf155msp/msp 
exhibit exencephaly similar to Trim71 mutant mice as a result of defective NSC 
proliferation and increased apoptosis.162 
PIK3CA, PTEN and MTOR are signaling genes of the PI3K pathway. PI3K pathway 
genes regulate cell growth, proliferation and differentiation in multiple tissues163, including 
NSCs in developing ventricular zone164. Somatic PIK3CA or MTOR gain-of-function 
(GoF) mutations and PTEN LoF mutations drive tumorigenesis by increasing PIP3 
levels165. Related germline or mosaic mutations have been identified in multiple brain and 
body overgrowth syndromes that also predispose to cancer.166 NSC-specific conditional 
expression of a Pik3ca activating allele during mouse embryogenesis induced 100% pen- 
etrant, severe nonobstructive murine hydrocephalus with focally increased NSC 
proliferation and disruption of cell adhesion at the neural-ependymal transition zone.167 
Pten conditional deletion in mouse NSCs causes increased PIP3 signaling and severe 
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obstructive hydrocephalus due to increased ventricular zone NSC proliferation and cell 
size, with associated cerebral aqueduct obliteration.168 mTOR inhibitor rapamycin can 
rescue the severe neonatal hydrocephalus associated with constitutive mTORC1 
hyperactivation in NSCs due to primary cilia ablation.167 
FOXJ1 encodes the forkhead family transcription factor Forkhead Box J1. Foxj1 
depletion in mice causes obstructive hydrocephalus and aqueductal stenosis and disrupts a 
transcriptional network required for the differentiation of radial glial NSC into multiciliated 
ependymal cells.169 Fmn2 overexpression disrupts neuroepithelial integrity and impairs 
NSC proliferation and neuronal migration in mouse embryos.170 Fmn2 and FlnA double 
knockout mice show significantly thinned cortices and microcephaly associated with NSC 
proliferation.171 Ptch1+/- mice develop hydrocephalus with incomplete penetrance and 
variable expressivity.172 Primary cilia sense gradients of Sonic Hedgehog via PTCH1, 
which transduces these signals to regulate growth and differentiation of hindbrain 
NSCs.173,174  
FXYD2 contains a significant burden of inherited dominant mutations, including a 
recurrent splice-site mutation 
To identify additional haplo-insufficient genes associated with CH otherwise not 
revealed by DNM analysis, we compared the observed and expected number of rare (minor 
allele frequency (MAF) ≤ 5.0 × 10−5) heterozygous LoF mutations in each gene using a 
one-tailed binomial test while adjusting for gene mutability (Methods). FXYD2 
(pLI = 0.24), encoding the regulatory γ-subunit of the Na+/K+-ATPase, surpassed genome-
wide significance thresholds (123.5-fold enrichment, P = 2.3 × 10−6; Fig. 9). No DNMs or 
recessive mutations were observed in FXYD2. Case–control burden analysis for rare LoF 
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mutations in all probands versus gnomAD controls also identified FXYD2 as having high 
mutational burden in CH probands (odds ratio = 49.3, one-sided Fisher’s exact test, 
P = 4.8 × 10−5). Three unrelated CH probands exhibited two identical transmitted canonical 
splice-site mutations in FXYD2 (c.299-1G>A) and one unphased FXYD2 splice-site 
mutation (c.410+1G>A) predicted by the CRYP-SKIP algorithm175 to cause exon skipping 
(Fig. 9). The maximum haplotype shared by the two kindreds (~548 kb) suggests a remote 
common ancestor (Supplementary Table 7 and Supplementary Fig. 2). Recurrent 
heterozygous missense mutations in FXYD2 (p.Gly41Arg) underlie defective Na+/K+-
ATPase plasma membrane expression and function in autosomal dominant type 2 renal 
hypomagnesemia (OMIM no. 154020). All FXYD2 mutant CH probands shared normal 
serum magnesium levels, and the majority displayed corpus callosum abnormalities and 













Fig. 9: Transmitted and unphased mutations in FXYD2. 
 
 
a, Pedigrees and sequencing electropherograms of Sanger sequencing depict all FXYD2 mutations in genomic DNA from 
CH probands. b, Representative T1 or T2-weighted brain magnetic resonance images for all available probands. c, The 
CRYP-SKIP algorithm prediction on splicing defects for FXYD2: c.299-1 G > A. d, The CRYP-SKIP algorithm 









Recessive genotypes in homologs of mouse hydrocephalus genes are enriched in 
consanguineous CH cases 
The 8.7% consanguinity of our CH cohort (Supplementary Table 2 and 
Supplementary Fig. 3) prompted evaluation for enrichment in CH probands of damaging 
recessive genotypes (RGs) in homologs of 189 mouse hydrocephalus (mH) genes7,176 
(Methods). Among 90 damaging RGs among probands, six occurred in the mH gene set, 
(P = 3.7 × 10−3) (Supplementary Table 8a). Enrichment of RGs in the mH gene set was 
greater for LoF mutations (P = 4.9 × 10−4; Supplementary Table 9). Homozygous RGs 
new for CH included one each in POMGNT1 (c.1111-1G>A), FKRP (D-Mis 
p.Gly354Glu), RHPN1 (p.Met281fs), CEP290 (c.6012-2A>G), KCNG4 (p.Gly442Arg) 
and KIF19 (p.Gly859fs) (Supplementary Table 8b and Fig. 10). All probands were 
products of consanguineous union except the RHPN1 proband, P = 1.9 × 10−3; 
Supplementary Table 10), revealing a substantial contribution of RGs among probands 
from consanguineous union (15.6%). Homozygous loss of each of these genes causes 
severe postnatal hydrocephalus.7,176 
Fig. 10: Damaging recessive genotypes in human dystroglycanopathy genes and 
homologs of mouse hydrocephalus genes. 
 
Available clinical-neuroimaging phenotypes of CH probands with damaging recessive mutations. 
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POMGNT1 and FKRP mutations cause human muscular dystrophy-
dystroglycanopathy, characterized by hypotonia, seizures, retinal degeneration, 
cobblestone lissencephaly and, rarely, ventriculomegaly.177 A set of 12 human muscular 
dystrophy-dystroglycanopathy genes was enriched among CH probands (P = 8.5 × 10−5; 
Supplementary Table 8a) and included POMGNT2, a gene with a homozygous 
(consanguineous) LoF mutation (p.Tyr367X) whose depletion causes hydrocephalus in 
humans and zebrafish (Supplementary Table 8b).178 Other pathway gene sets implicated 
in syndromic hydrocephalus7, including cilia structure and function, cell adhesion, synaptic 
vesicle biology, planar cell polarity, Ras signaling, Wnt signaling, PI3K-AKT-mTOR 
signaling and lysosomal storage were not enriched among CH probands (Supplementary 
Table 8a). 
CH risk genes converge in fetal human coexpression networks and cell types relevant 
for fetal neurogenesis 
Working from the supposition that CH-associated mutations in biologically 
pleiotropic genes may disrupt intersecting processes to contribute to a common 
phenotype129, we attempted to identify brain specific RNA co-expression networks and cell 







Fig. 11: CH risk genes are enriched in a coexpression network pertinent to other 
neurodevelopmental disorders and in cell types of early fetal neurogenesis. 
 
a, Enrichment analysis across weighted gene coexpression network analysis (WGCNA) modules of the midgestational 
human brain for genes with rare risk variation in CH (high confidence, probable risk and known human genes), ASD and 
DD (Methods contains details of gene set definitions). Only seven modules are shown (labeled by color in line with 
Walker et al.155); other modules demonstrated no significant enrichment for tested gene sets. Tiles labeled with −log10(P 
value) and an asterisk represent statistically significant enrichment at the Bonferroni multiple-testing cutoff 
(α = 0.05/17 = 2.94 × 10−3). b, Top 20 GO biological process terms and top 20 HP ontology terms enriched for the yellow 
module. The x axis depicts −log (adjusted P value) and the dotted line represents the α = 0.05 significance threshold. (P 
values are adjusted according to the g:SCS algorithm from g:Profiler158). c, Enrichment analysis across cell type markers 
of the midgestational human brain159 for genes with rare risk variation in CH (high confidence, probable risk and known 
human genes), ASD and DD. Tiles labeled with −log10(P value) and an asterisk represent significant enrichment at the 
Bonferroni multiple-testing cutoff (α = 0.05/16 = 3.13 × 10−3). 
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We tested whether high-confidence, probable and/or known human CH risk genes 
converge in gene coexpression networks of the midgestational human cortex (Methods).155 
Notably, CH risk genes converged in a single transcriptional network (‘yellow’ module; 
P = 1.19 × 10−3; Fig. 11a), previously associated with ASD and other undiagnosed 
developmental disorders (DDs).155 The top enriched Gene Ontology (GO) biological 
process terms for the yellow module (Fig. 11b) include neuronal differentiation and RNA 
processing (for example, GO: 0000904 and GO: 0048667). The top enriched human 
phenotype (HP) ontology terms (Fig. 11b) describe several congenital defects of 
craniofacial development and behavioral abnormalities, including ‘autistic behavior’ (for 
example, HP: 0000252 and HP: 0000729). 
We also examined potential enrichment of CH risk genes in cell type markers of 
the largest available single-cell (sc)RNA transcriptomic atlas of midgestational brain 
development44 (spanning 17–18 gestational weeks; Fig. 11c). High confidence and 
probable CH genes were enriched in nascent migrating excitatory neurons 
(P = 9.98 × 10−5). Adding known human genes to our cohort’s risk genes led to additional 
enrichment in mitotic progenitors PgS (P = 2.85 × 10−3) and PgG2M (P = 2.44 × 10−3). 
These data suggest that mutations in biologically pleiotropic CH genes disrupt pathways 
that regulate neurogenesis in the developing human brain. 
CH shares genetic risk factors with other neurodevelopmental disorders. 
The transcriptional overlap of risk genes for CH, ASD and DD during brain 
development (Fig. 4a); the frequent presence of other neurodevelopmental phenotypes in 
patients with CH;179 and the association of ventriculomegaly with ASD180 and other neuro- 
developmental conditions181 prompted our hypothesis that sporadic CH may share common 
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genetic risk factors with ASD and other neurodevelopmental conditions. Indeed, CH and 
ASD exhibited significant overlap, with 7 genes harboring LoF DNMs and 20 genes 
harboring damaging DNMs in both cohorts (Supplementary Table 12). CH and other DDs 
also exhibited significant overlap, with 6 genes harboring LoF DNMs and 22 harboring 
damaging DNMs in both cohorts (Supplementary Table 13). The data suggest partial 




















Our WES study of the largest cohort of sporadic, neurosurgically treated CH to date 
has coupled integrative genomics with deep clinical and neuroradiographic phenotyping to 
uncover new insights into CH genetic architecture and biology with potential implications 
for patient care. We show rare mutations with large effect contributed to 22.2% of CH 
cases (17.7% damaging DNMs, 1.6% RGs, 0.8% transmitted heterozygous LoF variants). 
Overall, 2.1% of CH cases represented known familial CH mutations. Insertion-deletions, 
rearrangements, noncoding variants and intronic splice mutations, also likely contribute to 
genetic risk for CH and will be subjects of future studies. Additional CH cases may arise 
from complex interactions between genetic and environmental risk factors. 
We estimate from the distribution of protein-altering DNMs in LoF-intolerant 
genes that 34 genes contribute to CH via a DNM mechanism (Supplementary Fig. 4a; 
Methods). This estimate is relatively low compared to the ~400 genes contributing to ASD 
and CHD, respectively.150,182 Simulations suggest that sequencing of 2,500 or 5,000 WES 
trios will yield 90.3% or 97.6% saturation, respectively for CH (Supplementary Fig. 4b; 
Methods). Sequencing of additional trios and isolated probands will therefore detect 
additional rare mutations with a large effect on disease risk. 
These results corroborate and significantly extend our previous work137, with 
discovery of new DNMs in TRIM71 and SMARCC1 as likely bona fide CH risk genes. We 
also provide evidence that PIK3CA, PTEN, MTOR, FOXJ1, FMN2, PTCH1 and FXYD2 
are new high-confidence sporadic CH genes, collectively accounting for ~7.3% of CH 
cases. The phenotypes associated with each orthologous gene in corresponding zebrafish 
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and/or murine disease models support their roles in embryonic neurogenesis and CH 
pathogenesis (Supplementary Table 11). 
Several of the identified CH risk genes harboring damaging DNMs and inherited 
mutations have been implicated in other Mendelian diseases, sometimes producing quite 
different phenotypes. For example, three CH probands carried mutations in PTEN 
previously implicated in PTEN hamartoma tumor syndrome (OMIM no. 607174), but none 
met criteria for this or related PTEN disorders.183-185 The same is true of a CH proband 
harboring an MTOR mutation previously implicated in Smith–Kingsmore syndrome 
(OMIM no. 616638) that did not meet criteria for this disorder.186 Similarly, although the 
identical FOXJ1 DNMs in our CH probands were recently identified in patients with type 
43 primary ciliary dyskinesia (OMIM no. 618699, associated with bronchiectasis and situs 
inversus)187, none of our FOXJ1 mutant patients exhibit these pulmonary or cardiac 
phenotypes. These observations highlight the phenotypic heterogeneity and variable 
expressivity associated with these gene mutations, which could arise from environmental 
modifiers, working in concert with the identified rare mutations and/or specific genetic 
modifiers, including mosaicism and other somatic mutations. 
Much hydrocephalus research has centered on understanding the production, 
circulation and reabsorption mechanisms of CSF. While these mechanisms are important 
for acquired hydrocephalus in children and adults or in elderly patients with normal 
pressure hydrocephalus, our data and much murine data176 implicate earlier, more 
fundamental genetic insults in CH. Notably, each high confidence CH gene harboring 
DNMs is highly expressed in the neuroepithelium lining embryonic neural tube and/or 
ventricular (VZ) and subventricular (SVZ) zones, where they regulate proliferation, 
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differentiation and/or fate specification of multipotent NSCs or rapidly proliferative neural 
precursors. Genetic disruption of embryonic and fetal brain development is therefore the 
primary event underlying CH pathogenesis in a significant subset of patients. 
In this NSC model of CH pathogenesis (Fig. 5), nonobstructive ventriculomegaly 
can result from impaired neurogenesis due to dysregulation in NSC pluripotency, leading 
to decreased cortical cell mass and a thinned cortical mantle.188 Obstructive 
ventriculomegaly can arise from progressive CSF accumulation due to aqueductal 
obstruction from maldevelopment189 or to peri-aqueductal NSC hyperproliferation190. 
Other potential mechanisms include impaired growth or size regulation of the ventricular 
apical domain of primary cilia-containing radial glia NSCs191 or impaired differentiation 
of radial glia NSCs into multiciliated ependymal cells.169 These primary genetic events 
impairing neuro-gliogenesis could then secondarily disrupt CSF homeostasis by altering 
normal multiciliated ependymal or possibly glia-lymphatic structure and function. Notably, 
germinal matrix hemorrhage in premature neonates, the most common cause of acquired 
pediatric hydrocephalus, is associated with impaired neurogenesis due to ependymal 
denudation and NSC damage in the VZ-SVZ.192 An NSC model could thus provide a 













Fig. 5: A neural stem cell model of sporadic CH. 
 
Schematic of the normal developing brain with the ventricular system surrounded by parenchyma consisting of neurons, 
astrocytes and components of neurogenesis at the cellular level (top). Embryonic and fetal NSC populations, including 
neuroepithelial cells and radial glia cells (RGCs), together generate virtually all neuronal and glial cells that populate the 
brain, including multiciliated ependymal cells that line the ventricular system thought to participate in CSF circulation 
and maintenance of ventricular integrity. Defects in embryonic and fetal NSCs secondary to genetic mutations can thus 
drive CH via multiple pathogenic mechanisms that impact development and maturation of different cell types. Schematic 
of two possible developmental mechanisms of NSC alteration that may lead to ventriculomegaly (bottom). In one 
hypothesized scenario (left), ventriculomegaly results from impaired neurogenesis and an associated decrease in cortical 
cell mass that reflects a reduction in NSC proliferation. Continued CSF production from the unaffected choroid plexus 
would further expand the already enlarged ventricular compartment and even at low hydrostatic pressure push the thin, 
low-resistance cortical ribbon to the dural–bone interface. Ventricular enlargement and dysmorphology could then 
promote further ventricular expansion through secondary disruption of normal linear CSF laminar flow, eliciting fluid 
turbulence and current reversal. In another hypothesized scenario (right) that is not necessarily mutually exclusive from 
the former, altered NSC regulation leads to malformation of ependymal cells and their motile cilia, leading to impaired 
intraventricular CSF circulation and attendant CSF accumulation responsible for progressive ventricular dilation. 
Furthermore, defects in cilia-related genes may cause hydrocephalus not only by impairing motile cilia-driven CSF flow, 
but also by affecting development of primary cilia, which are nonmotile sensory organelles present on embryonic and 
fetal NSCs, crucial for multiple developmental processes, including patterning, neurogenesis, migration and survival. A 
combination of defects in NSC patterning and/or the proliferation–differentiation balance can also introduce anatomical 
defects, resulting in physical obstruction to CSF flow, such as aqueductal stenosis. 
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Consistent with mutations impacting fundamental aspects of fetal brain 
development, associated phenotypes such as intellectual disability, neurodevelopmental 
delay, epilepsy and autistic-like features are not infrequent findings among patients with 
CH193, including those of our cohort. In addition, ventricular enlargement in low-birth-
weight infants is a risk factor for ASD194, including those with de novo PTEN mutations. 
We found enriched overlap of genetic risk factors between CH and ASD and DDs, along 
with CH risk gene enrichment in coexpression networks previously implicated in these 
conditions. However, analysis showed convergence of CH risk genes in neural precursors 
of relatively earlier origin than those of ASD and DDs195, perhaps accounting for the 
increased frequency of structural brain abnormalities in CH probands relative to these other 
disorders. The power of integrative genomics to identify specific cell types and 
developmental pathways impacted by CH genes will be increased as more high-confidence 
CH risk genes are discovered. 
The diversity of genetic etiologies and underlying biochemical pathways in CH 
supports implementation of routine clinical WES for newly diagnosed patients. Current 
recommendations for workup of fetal/neonatal ventriculomegaly include rapid testing for 
known chromosomal and copy-number abnormalities.196 However, this strategy does not 
address CH cases explained by known mutations. Application of routine WES or whole 
genome sequencing would provide improved diagnosis and management of children with 
CH. WES or whole genome sequencing could also aid prognostication, increase vigilance 
for medical screening of mutation-associated conditions (such as cancer surveillance for 
patients with CH with PIK3CA or PTEN) and provide recurrence rates to restore 
reproductive confidence. 
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In the longer term, we speculate that WES of patients with CH, coupled with deep 
clinical and neuroradiographical phenotyping, might improve precision of classification 
schemes to prognosticate neurocognitive outcomes and stratify patients to specific 
treatments (such as endoscopy versus CSF shunting versus pharmacological therapies). For 
example, in some nonobstructive CH with excessively thinned cortical mantles from 
disrupted neurogenesis and normal or even borderline moderately elevated ICPs, surgical 
CSF shunting may merely expose patients with CH to surgical morbidity without 
addressing disease pathogenesis. Surgical intervention in these contexts is unlikely to 
improve associated neurodevelopmental phenotypes such as seizures, motor impairment or 
intellectual function, more likely arising from genetic disruptions of embryonic 
neurogenesis than from reversible sequelae of CSF accumulation. These observations 
should raise thresholds for surgical intervention (or subsequent shunt revision) in patients 
with CH without obstruction, high ICPs or high-pressure-associated symptoms. 
Our data explain ~20% of CH cases; however, most sporadic CH cases remain 
unexplained. Our current sample size still lacks statistical power adequate to detect the 
many rare, inherited or sporadic CH-associated risk genes. Although our patients are 
mostly of European origin, international collaborative studies will soon overcome our 
current limitations of small cohort size and limited ethnic diversity. Moreover, mechanistic 
insights into newly identified CH causal genes and core pathways will arise from in vivo 
experiments in model organisms. Our current work identifying new human gene targets 
will serve as entry points for these functional studies. Successful pursuit of these next steps 
will refine current heuristics for clinical decision-making and render personalized 
treatments for patients with CH, including nonsurgical targeted therapies, a realistic goal. 
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IX. Supplementary Figures and Tables 
Supplementary Figure 1: De novo mutation rate closely approximates Poisson 
distribution in 225 known-CH-gene-negative CH cases and controls. Observed number 
of de novo mutations per subject (bars) compared to the numbers expected (line) from the 
Poisson distribution in the case (red) and control (blue) cohorts. ‘p' denotes two-tailed chi-




Supplementary Figure 2. Estimation of the mutation age for FXYD2 . Mutation age 
(the number of generations, x-axis) was estimated using DMLE+2.3 software based on a 
Bayesian inference approach. A total of 1,000,000 iterations were performed. The y-axis 
shows the relative frequency of occurrences for each mutation age estimate. The optimum 
population growth rate (PGR) and the proportion of sampled chromosome (PSC) for 
FXYD2c.299-1G>A mutation in the Western European ancestry were estimated to be 0.17 
and 0.0000476, respectively. The average mutation age is 52.4 and the 95% confidence 
interval is between 35.7 and 68.6.  
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Supplementary Figure 3. Significant difference in the degree of consanguinity 
between cases and controls. Red and blue dots represent the longest homozygosity-by-
descent (HBD) segments and inbreeding coefficients of case (A) or control (B) subjects, 
respectively. For reference, the ticks of the x-axis correspond to the inbreeding coefficient 
for third, second, first cousin, and half-siblings (from smallest to largest). The distribution 
of the mean inbreeding coefficient (C) and longest HBD segment (D) respectively between 













Supplementary Figure 4. CH gene discovery projections. (A) Estimation of the number 
of CH risk genes via de novo mechanism. Monte Carlo simulation was performed based 
on observed protein-altering de novo mutations in 3,049 loss-of-function intolerant genes 
(pLI ≥ 0.9 in gnomAD [v2.1.1]) using 20,000 iterations. We estimate that the number of 
risk genes via de novo events to be ~34. (B) Estimation of the number of recurrent genes. 
The number of trios and the number of genes with more than one protein- altering de novo 
mutation are specified on the x and y-axis, respectively. We modeled the expected rate of 
protein altering de novo mutations given an increasing sample size. 10,000 iterations were 
performed to estimate the number of genes with more than 1 protein-altering de novo 
mutations, taking into account the probability of de novo protein-altering mutation. WES 
of 2,500 and 5,000 trios are expected to yield a 90.3% and 97.6% saturation rate, 





# of case trios 232
# of case singletons 149
# of control trios 1,798
Supplementary Table 1. Number of studied cases and controls




CH Cases  Autism Sibling Controls
Sample size 381 1,798
Gender
Male 183 (48.0%) 842 (46.8%)
Female 198 (52.0%) 956 (53.2%)
European 304 (79.8%) 1,418 (78.9%)
African American/African* 34 (8.9%) 77 (4.3%)
East Asian 0 (0.0%) 40 (2.2%)
South Asian 7 (1.8%) 88 (4.9%)
Mexican 24 (6.3%) 129 (7.2%)
Other 12 (3.2%) 46 (2.6%)
Yes 33 (8.7%) 23 (1.3%)
No 348 (91.3%) 1,775 (98.7%)
Non-communicating 211 (55.4%) N/A
Communicating 123 (32.3%) N/A
Unknown/Indeterminate 47 (12.3%) N/A
Positive 8 (2.1%) N/A
Negative 373 (97.9%) N/A
* 26 out of 34 classified African Americans/Africans were recruited via the CURE Children’s 
Hospital of Uganda. Of note, recent studies have suggested modern Ugandans show distinct 
genetic substructure from the HapMap African African populations (Gurdasani 2015 
[10.1038/nature13997]; Gurdasani 2019 [10.1016/j.cell.2019.10.004]). The number of samples 
is shown in each category with the corresponding percentage in parentheses. Ethnicity is 
determined by principal component analysis compared to HapMap samples using 
EIGENSTRAT. The criteria of consanguinity are defined as homozygosity in segments of 2cM 
or greater length that collectively comprise at least 0.35% of the genome. Known CH genes 
include L1CAM , CCDC88C , MPDZ , AP1S2 , EML1 , WDR81 , FLNA ,  and CRB2 .
Supplementary Table 2. Demographic characteristics of CH cases and controls 
Ethnicity 
Truly Consanguineous
Type of Congenital Hydrocephalus
Known CH Gene Mutation Status
Cases Cases Controls
(MedExome; N=97) (xGen IDT; N=748)
& (Roche V2; N=5,394)
Read length (bp) 101-148 101 50-99
# of reads per sample (M) 53.1 56.4 111.5
Median coverage at each targeted base (X) 39.2 59.1 68
Mean coverage at each targeted base (X) 45.8 63.2 80.8
% of all reads that map to target 48.80% 57.70% 46.50%
% of all bases that map to target 39.20% 43.40% 35.70%
% of targeted bases read at least 8x 96.50% 98.40% 92.70%
% of targeted bases read at least 10x 95.30% 98.10% 91.40%
% of targeted bases read at least 15x 90.50% 96.60% 87.80%
% Mean error rate 0.30% 0.30% 0.50%
Supplementary Table 3. Summary sequencing statistics for the CH case and control cohorts
Category
&
97 case samples were sequenced using the MedExome capture reagent.  All other samples were sequenced 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































117309495 rs10892104 0.395 A G A|G A|G G|G G|G G|G G|A
117309527 rs75808396 0.143 A G A|G A|G G|G G|G G|G G|A
117309581 rs61905269 0.11 G G G|G G|G G|G G|A G|G A|G
117329415 rs520328 0.112 G/A G G/A G/A G/A G|G G|G G|G
117332343 rs2298766 0.238 C C C|C C|C C|C C|T C|C T|T
117332352 rs588048 0.995 G G G|G G|G G|G G|G G|G G|G
117335722 rs538847 0.647 T/C T T/C T/C T/C T|C T|T C|C
117335991 rs663191 0.059 C C C|C C|C C|T C|C C|C C|C
117351353 rs577166 0.06 C C C|C C|C C|T C|C C|C C|C
117375596 rs2276343 0.188 G G G|G G|G G|A G|G G|G G|G
117375853 rs141701802 0.005 C C C|C C|C C|C C|C C|T C|C
117389517 rs3819210 0.209 A A A|A A|A A|G A|A A|A A|A
117391736 rs7936795 0.152 A A A|A A|A A|G A|A A|A A|A
117391966 rs2276340 0.153 G G G|G G|G G|A G|G G|G G|G
117392110 rs35503235 0.032 A A A|A A|A A|A A|A A|G A|A
117395481 rs2276339 0.208 G G G|G G|G G|A G|G G|G G|G
117403017 rs7109567 0.618 G G G|G G|G G|A G|G G|A G|G
117403235 rs3741280 0.351 G G G|G G|G G|T G|G G|T G|G
117647461 rs73587457 0.101 C C C|G C|C G|C C|C C|C C|C
117667688 rs113876980 0.221 C C C|C C|A C|A C|C C|A C|A
117691386 rs869789 0.135 G G G|A G|G A|G G|G G|G G|G
117693196 *c.299-1G>A* 1.6x10
-5 T T T|C T|C C|C T|C T|C C|C
117693255 rs529623 0.458 T T T|T T|C T|C T|T T|C T|C
117698762 rs7117314 0.317 G G G|G G|G G|A G|G G|A G|A
117772848 rs491822 0.405 C/T T C/T C/T C/T T|C T|C C|C
117773110 rs494457 0.959 C C C|C C|C C|C C|C C|C C|C
117774146 rs2186627 0.27 C C C|G C|C G|C C|G C|G G|G
117774291 rs2845712 0.878 C C C|C C|C C|C C|C C|C C|C
117776471 rs3802873 0.253 C C C|C C|C C|C C|T C|T T|T
117776526 rs3802872 0.457 A/G G A/G A/G A/G G|A G|A A|A
117779612 rs947969 0.495 G/A A G/A G/A G/A A|G A|G G|G
117780744 rs12801855 0.115 C/T C C/T C/T C/T C|C C|C C|C
117781435 rs2155194 0.952 G G G|G G|G G|G G|G G|G G|G
117782638 rs2277288 0.297 A A A|A A|A A|A A|G A|G G|G
117784434 rs11605749 0.245 G G G|C G|C C|C G|G G|G G|G
117784714 rs11216618 0.195 T/C T T/C T/C T/C T|T T|T T|T
117785260 rs4936410 0.242 C C C|T C|T T|T C|C C|C C|C
117799923 rs7928668 0.608 T T/C T|T T|T T|T T/C T/C T/C
117800033 rs35251396 0.043 G G G|G G|G G|G G|G G|A G|G
117800083 rs10892196 0.607 T T/C T|T T|T T|T T/C T/C T/C
117857338 rs10892202 0.12 G G G|G G|C G|G G|G G|G G|C
117858983 rs4252248 0.71 G A G|A G|A A|A A|A A|A A|A
117859209 rs4252249 0.121 G G G|G G|A G|G G|G G|G G|A
The inferred haplotype for SNPs flanking FXYD2
c.299-1G>A
 mutation in 2 kindreds (KCHYD99 and KCHYD131) are shown. The maximum haplotype shared 
by 2 kindreds is ~548kb, indicated by gray. To the right of the columns showing inferred haplotypes, the genotypes (GT) of SNPs at each position in each 
family member are indicated. Chr 11 Pos., position on chromosome 11 in hg37; rs#, SNP identifier in dbSNP database (the novel mutation shared by 2 
kindreds is denoted by *c.299-1G>A*); Bravo Freq: frequency of minor allele in the Bravo database. 
Supplementary Table 7. Haplotypes flanking FXYD2
c.299-1G>A






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































All genes (19,347) 28 2 30 30 - - -
Mouse hydrocephalus genes (189) 4 0 4 4 0.37 10.79 4.9x10
-4
Dystroglycanopathies (12) 2 0 2 2 0.02 103.76 1.8x10
-4
Ciliopathies genes (22) 1 0 1 1 0.06 16.47 0.06
Cell adhesion molecules (142) 1 0 1 1 0.22 4.62 0.2
Wnt signaling pathway (156) 0 0 0 0 0.25 0 1
1,798 Controls
All genes (19,347) 6 6 12 12 - - -
Mouse hydrocephalus genes (189) 0 0 0 0 0.21 0 1
Dystroglycanopathies (12) 0 0 0 0 8.1x10
-3
0 1
Ciliopathies genes (22) 0 0 0 0 0.05 0 1
Cell adhesion molecules (142) 0 0 0 0 0.08 0 1
Wnt signaling pathway (156) 0 0 0 0 0.11 0 1
Supplementary Table 9. Loss-of-function recessive genotypes in the mouse hydrocephalus and dystroglycanopathies gene sets are more 
enriched in CH cases compared to damaging recessive genotypes.















All genes (19,347) 50 1 51 51 - - -
Mouse hydrocephalus genes (189) 5 0 5 5 0.89 5.63 1.9x10
-3
Dystroglycanopathies (12) 2 0 2 2 0.05 37.02 1.4x10
-3
Ciliopathies genes (22) 1 0 1 1 0.16 6.14 0.15
Cell adhesion molecules (142) 1 0 1 1 0.41 2.43 0.34
Wnt signaling pathway (156) 1 0 1 1 0.69 1.45 0.5
341 Non-Consanguineous Cases
All genes (19,347) 19 20 38 39 - - -
Mouse hydrocephalus genes (189) 1 0 1 1 0.58 1.72 0.44
Dystroglycanopathies (12) 1 0 1 1 0.03 35.26 0.03
Ciliopathies genes (22) 0 0 0 0 0.12 0 1
Cell adhesion molecules (142) 0 0 0 0 0.27 0 1
Wnt signaling pathway (156) 0 0 0 0 0.43 0 1
Supplementary Table 10. Damaging recessive genotypes in the mouse hydrocephalus and dystroglycanopathies gene sets are 
more enriched in 32 consanguineous cases compared to 341 non-consanguineous cases.

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Observed # genes Expected # genes Enrichment Empirical P-value
Genes with LoF de novo mutations overlapping 
between CH and Autism cohorts
7 2.72 2.57 0.0164
Genes with damaging de novo mutations 
overlapping between CH and Autism cohorts
20 13.77 1.45 0.0494
Supplementary Table 12. Enrichment of overlapping genes with LoF or damaging de novo mutations between CH and Autism cohorts
106 permutations were performed to estimate the empirical distribution of the number of overlapping genes between CH and Autism cohorts. The 
empirical p-value is calculated as the proportion of the expected number of overlapping genes that exceeds the observed number of overlapping genes. 
For the detailed approach, please see Online Methods.*The Autism cohort refers to: (1) Satterstrom 2020 (10.1016/j.cell.2019.12.036)
CH cohort
Autism cohort*
Unique genes with LoF de 
novo mutations
N = 36 N = 813
729






Observed # genes Expected # genes Enrichment Empirical P-value
Genes with LoF de novo mutations 
overlapping between CH and DD cohorts
6 2.3 2.61 0.0253
Genes with damaging de novo mutations 
overlapping between CH and DDD cohorts
22 13.12 1.68 0.0083
Supplementary Table 13. Enrichment of overlapping genes with LoF or damaging de novo mutations between CH and DD cohorts
106 permutations were performed to estimate the empirical distribution of the number of overlapping genes between CH and DD cohorts. The 
empirical p-value is calculated as the proportion of the expected number of overlapping genes that exceeds the observed number of overlapping 
genes. For the detailed approach, please see Methods.*The DD cohort refers to: (1) DDD 2017 (10.1038/nature21062)
CH cohort
DD cohort*
Unique genes with LoF de 
novo mutations
N = 36 N = 673
630
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